Welcome to the UPF Digital Repository

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension

Show simple item record

dc.contributor.author Codina, Pau
dc.contributor.author Domingo, Mar
dc.contributor.author Barceló, Helena
dc.contributor.author Gastelurrutia, Paloma
dc.contributor.author Casquete,Daniel
dc.contributor.author Vila, Joan
dc.contributor.author Abdul-Jawad Altisent, Omar
dc.contributor.author Spitaleri, Giosafat
dc.contributor.author Cediel, German
dc.contributor.author Santiago-Vacas, Evelyn
dc.contributor.author Zamora, Elisabet
dc.contributor.author Ruiz-Cueto, María
dc.contributor.author Santesmases, Javier
dc.contributor.author de la Espriella, Rafael
dc.contributor.author Pascual-Figal; Domingo A.
dc.contributor.author Núñez, Julio
dc.contributor.author Lupón, Josep
dc.contributor.author Bayes-Genis, Antoni
dc.date.accessioned 2022-10-26T07:09:30Z
dc.date.available 2022-10-26T07:09:30Z
dc.date.issued 2022
dc.identifier.citation Codina P, Domingo M, Barceló E, Gastelurrutia P, Casquete D, Vila J, et al. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Fail. 2022 Aug; 9(4): 2170-80. DOI: 10.1002/ehf2.13952
dc.identifier.issn 2055-5822
dc.identifier.uri http://hdl.handle.net/10230/54595
dc.description.abstract Aims: prior studies have not fully characterized the haemodynamic effects of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan in heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH). The aim of the Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device (ARNIMEMS-HFpEF) study is to assess pulmonary artery pressure (PAP) dynamics by means of implanted PAP monitors in patients with HFpEF-PH treated with sacubitril/valsartan. Methods and results: this single-arm, investigator-initiated, interventional study included 14 consecutive ambulatory symptomatic HFpEF-PH patients who underwent CardioMEMS implantation prior to enrolment [mean ejection fraction 60.4 ± 7.2%, baseline mean PAP (mPAP) 33.9 ± 7.6 mmHg]. Daily PAP values were examined during three periods: a 6 week period after CardioMEMS implantation and before sacubitril/valsartan treatment (pre-ARNI), a 6 week period with sacubitril/valsartan treatment (ARNI ON), and a 6 week period of sacubitril/valsartan withdrawal (ARNI OFF). The primary endpoint was change in mPAP with and without sacubitril/valsartan. Secondary endpoints included changes in 6 min walking distance, B-line sum in lung ultrasound, and quality of life (QoL). During the study period, 1717 mPAP measurements were recorded. Between pre-ARNI vs. ARNI ON, mPAP significantly declined by -4.99 mmHg [95% confidence interval (CI) -5.55 to -4.43]. Between ARNI ON vs. ARNI OFF, mPAP significantly increased by +2.84 mmHg [95% CI +2.26 to +3.42]. Between pre-ARNI vs. ARNI ON, we found an improvement in 6 min walking distance, B-lines, and QoL. Mean loop diuretic management did not differ between periods. Conclusions: sacubitril/valsartan significantly reduced mPAP in patients with HFpEF-PH, independent of loop diuretic management, together with improvement in functional capacity, lung congestion, and QoL. Sacubitril/valsartan may be a therapeutic alternative in HFpEF-PH.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.rights Copyright © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.title Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1002/ehf2.13952
dc.subject.keyword ARNI
dc.subject.keyword Heart failure
dc.subject.keyword Preserved LVEF
dc.subject.keyword Pulmonary artery pressure
dc.subject.keyword Pulmonary hypertension
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking